Home » Archive

Articles in the Headline Category

Headline, News »

[Nov 3, 2010 4:04 pm | 2 Comments]
Researchers Identify Factors Associated With Improved Survival In Myeloma Patients After Surgery For Skeletal Complications

Early-stage myeloma, single bone lesions, a negative bone marrow biopsy, and normal M-protein levels in the serum are associated with improved survival in multiple myeloma patients following surgery for skeletal complications, according to a recent German study.

Multiple myeloma is commonly associated with a number of skeletal complications, including fractures, spinal cord compression, elevated calcium levels in the blood, and severe bone pain.

These complications arise as a result of skeletal weakening due to bone lesions. Bone lesions are the …

Headline, Opinion »

[Nov 2, 2010 2:53 pm | 8 Comments]
Sean’s Burgundy Thread: My Adventures Through Total Therapy

In November of 2008, my local physician referred me to specialists at the University of Arkansas for Medical Sciences (UAMS) for a diagnostic work-up, and it was there that his suspicions were confirmed. I, indeed, at 49 years old, had multiple myeloma. Whatever the heck that was!

My first order of business, after learning how to say ‘myeloma,’ was to seek qualified information and opinions from respected myeloma centers around the country, to interview knowledgeable physicians and oncology nurses, and …

Headline, News »

[Nov 1, 2010 4:59 pm | Comments Off]
Detection Of Rapidly Dividing Plasma Cells May Lead To More Targeted Treatment For Multiple Myeloma Patients

A recent study demonstrated that it is possible to identify multiple myeloma patients with a poor prognosis, based on the presence of rapidly dividing, or proliferating, cancerous cells. Classifying rapidly dividing myeloma cells as a prognostic factor may help patients receive more targeted treatment, especially as anti-proliferative drugs become available.

“Proliferation has long been known to be an adverse prognostic factor in myeloma, but it is quite laborious to measure it in the laboratory, and is thus not routinely measured …

Headline, News »

[Oct 29, 2010 3:13 pm | Comments Off]
Patients With Myeloma Precursor Disease MGUS May Have An Increased Risk Of Developing Blood Clots

Patients with monoclonal gammopathy of undetermined significance have an increased risk of developing blood clots, according to a recent study published in the European Journal of Haematology. Blood clots were also associated with poor survival in these patients.   

“Our findings underline the risk of VTE [blood cots] in the monoclonal gammopathies in general and might in this way serve to increase the awareness of this complication in myeloma patients,” stated Dr. Henrik Gregersen, of the Aalborg Hospital in Denmark and …

Headline, Opinion »

[Oct 28, 2010 12:11 pm | 4 Comments]
Pat’s Place: Flying The “Friendly Skies” With Multiple Myeloma

Air travel can be challenging, especially with an ongoing health condition. Multiple myeloma is certainly no exception. Busy airports, long security lines, and packed planes can be frustrating or even bad for your health.

Here are a few things multiple myeloma patients can do to in preparation for flying:

1. Don’t forget your address book. It is important to have all of your medical contact info with you when you travel, including your doctors’ phone numbers and insurance information. …

Headline, News »

[Oct 27, 2010 1:11 pm | 2 Comments]
Prolia May Delay The Onset Of Bone Complications More Effectively Than Zometa In Multiple Myeloma Patients

The pharmaceutical company Amgen recently announced that its new drug Prolia more effectively prevents bone pain and fractures in patients with advanced bone disease than Zometa. Prolia was noted to have higher efficacy in patients with various types of cancers, including multiple myeloma. The announcement followed the presentation of results from recent Phase 3 trials at the European Society of Medical Oncology Annual Meeting. 

Bone disease is frequently associated with multiple myeloma and can cause bone …

Headline, News »

[Oct 26, 2010 4:47 pm | Comments Off]
Velcade Maintenance Shows Little Improvement For Myeloma Patients Who Fail To Achieve Complete Response Post-Transplant

The use of single-agent Velcade as maintenance therapy does not significantly improve the response of multiple myeloma patients who fail to achieve a complete response following stem cell transplantation with their own cells, according to a recent study published in the journal Investigational New Drugs.

The researchers recommended that Velcade be used in combination with other myeloma treatments as maintenance therapy. “Velcade is indeed effective in the post-transplant setting, but it must be given as part of a combination therapy …